Pharma DECODED
Latest edition: 16 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
KRAS inhibitors: The next frontier beckons
There has been several developments in the KRAS inhibitor space, shaping the KRAS inhibitors of the future.
Latest news
FDA approves Bristol Myers Squibb's Breyanzi for follicular lymphoma
The approval is based on results from the open-label, global, multi-centre, single-arm Phase II TRANSCEND FL clinical trial.
Takeda's dengue vaccine obtains WHO prequalification
The TAK-003 vaccine targets all four virus serotypes.
FDA rejects label expansion for Dynavax's hepatitis B vaccine
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
Tracking the opioid lawsuit settlements amidst calls for oversight
The US National Opioid Settlement is distributing more than $54 billion to communities grappling with the opioid crisis.
Vanda Pharmaceuticals reports positive data from motion sickness trial
In the trial, only 10.4% and 18.3% of the subjects reported vomiting on the 170mg and 85mg doses, respectively.
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
The primary goal of the study is to measure progression-free survival.
Allucent receives grant for decentralised Covid-19 vaccine trial
The company received the award to conduct a trial assessing correlates of protection following Covid-19 vaccination.
In our previous edition
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Pharma Decoded
RAPT terminates Phase II trials for lead candidate following clinical hold
13 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer